Patents by Inventor Kang Dai

Kang Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210066914
    Abstract: Provided are a load transfer method and system in thunder and lightning weather. The method includes: detecting lightning and predicting a position and time of a lightning strike to obtain a lightning prediction result; determining a transmission line possibly struck by lightning in a power grid according to the lightning prediction result; determining a load transfer scheme; and before the lightning occurs, transferring at least part of loads on the transmission line possibly struck by lightning according to the load transfer scheme.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 4, 2021
    Inventors: Yunfeng CAI, Chong TONG, Ning WANG, Yang XU, Huiwen LU, Kang DAI, Wei YIN, Bowen WU, Liang WANG, Jianqiang MIAO
  • Publication number: 20200059093
    Abstract: Disclosed are a dynamic lightning protection method and system. The method includes detecting lightning in real time and tracking a position of a thunderstorm; and performing dynamic lightning protection and control on an electrical grid according to an electrical grid control strategy before the thunderstorm reaches or affects the electrical grid. Further disclosed is a dynamic lightning protection system.
    Type: Application
    Filed: July 13, 2018
    Publication date: February 20, 2020
    Inventors: Chong TONG, Yunfeng CAI, Ziyang ZHANG, Qing WANG, Kang DAI, Wei YIN
  • Publication number: 20160368933
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: April 22, 2016
    Publication date: December 22, 2016
    Inventors: Xiaoqi CHEN, Kang DAI, Jason DUQUETTE, Michael W. GRIBBLE, JR., Justin N. HUARD, Kathleen S. KEEGAN, Zhihong LI, Sarah E. LIVELY, Lawrence R. MCGEE, Mark L. RAGAINS, Xianghong WANG, Margaret F. WEIDNER, Jian ZHANG
  • Patent number: 9359355
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 7, 2016
    Assignee: AMGEN INC.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • Patent number: 8980903
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: March 17, 2015
    Assignee: Amgen Inc.
    Inventors: Richard V. Connors, Kang Dai, John Eksterowicz, Pingchen Fan, Benjamin Fisher, Jiasheng Fu, Kexue Li, Zhihong Li, Lawrence R. McGee, Rajiv Sharma, Xiaodong Wang, Dustin L. McMinn, Jeffrey T. Mihalic, Jeffrey Deignan
  • Publication number: 20140350244
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventors: Richard V. Connors, Kang DAI, John EKSTEROWICZ, Pingchen FAN, Benjamin FISHER, Jiasheng FU, Kexue LI, Zhihong LI, Lawrence R. MCGEE, Rajiv SHARMA, Xiaodong WANG, Dustin L. MCMINN, Jeffrey T. MIHALIC, Jeffrey DEIGNAN
  • Publication number: 20140163052
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: November 25, 2013
    Publication date: June 12, 2014
    Applicant: AMGEN INC.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • Patent number: 8623885
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 7, 2014
    Assignee: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • Patent number: 8389533
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are gem-disubstituted or spirocyclic pyridine, pyrimidine and triazine derivatives.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: March 5, 2013
    Assignee: Amgen Inc.
    Inventors: Richard V. Connors, Kang Dai, John Eksterowicz, Pingchen Fan, Benjamin Fisher, Jiasheng Fu, Kexue Li, Zhihong Li, Lawrence R. McGee, Rajiv Sharma, Xiaodong Wang
  • Publication number: 20120244110
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 27, 2012
    Applicant: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • Publication number: 20110142796
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.
    Type: Application
    Filed: December 18, 2008
    Publication date: June 16, 2011
    Applicant: Amgen Inc
    Inventors: Richard V. Connors, Kang Dai, John Eksterowicz, Pingchen Fan, Benjamin Fisher, Jiasheng Fu, Kexue Li, Zhihong Li, Lawrence R. Mcgee, Rajiv Sharma, Xiaodong Wang, Dustin L. Mcminn, Jeffrey T. Mihalic, Jeffrey Deignan
  • Publication number: 20110097305
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-me-dialed disorders, such as cancer. The subject compounds arc gem-disubstituted or spimcyclic pyridine, pyrimidine and triazine derivatives.
    Type: Application
    Filed: April 6, 2009
    Publication date: April 28, 2011
    Applicant: AMGEN INC.
    Inventors: Richard V. Connors, Kang Dai, John Eksterowicz, Pingchen Fan, Benjamin Fisher, Jiasheng Fu, Kexue Li, Zhihong Li, Lawrence R. Mcgee, Rajiv Sharma, Xiaodong Wang
  • Publication number: 20090226436
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.
    Type: Application
    Filed: April 9, 2009
    Publication date: September 10, 2009
    Inventors: Hui Tian, Kang Dai, Jin-Long Chen, Jiagang Zhao, Gene Cutler
  • Patent number: 7572783
    Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: August 11, 2009
    Assignee: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Richard Victor Connors, Kang Dai, Ying Fu, Juan C. Jaen, Yong-Jae Kim, Leping Li, Mike E. Lizarzaburu, Jeffrey T. Mihalic, Stephen J. Shuttleworth
  • Publication number: 20080113449
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.
    Type: Application
    Filed: January 9, 2008
    Publication date: May 15, 2008
    Inventors: Hui Tian, Kang Dai, Jin-Long Chen, Jiagang Zhao, Gene Cutler
  • Publication number: 20070141644
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.
    Type: Application
    Filed: February 28, 2007
    Publication date: June 21, 2007
    Inventors: Hui Tian, Kang Dai, Jin-Long Chen, Jiagang Zhao, Gene Cutler
  • Publication number: 20070135425
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
    Type: Application
    Filed: January 5, 2007
    Publication date: June 14, 2007
    Applicant: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Pingchen Fan, Shugui Huang, Leping Li, Jeffrey Mihalic
  • Publication number: 20070078152
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and/or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.
    Type: Application
    Filed: December 16, 2005
    Publication date: April 5, 2007
    Inventors: Xiaoqi Chen, Kang Dai, Pingchen Fan, Ying Fu, Leping Li, Jeffrey Mihalic
  • Publication number: 20060199796
    Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
    Type: Application
    Filed: August 12, 2005
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Richard Connors, Kang Dai, Ying Fu, Juan Jaen, Yong-Jae Kim, Leping Li, Mike Lizarzaburu, Jeffrey Mihalic, Stephen Shuttleworth
  • Patent number: 7045527
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and/or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: May 16, 2006
    Assignee: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Pingchen Fan, Ying Fu, Leping Li, Jeffrey T. Mihalic